Tenax Therapeutics Inc

NASDAQ:TENXUnited States

Nov 13, 2024

Show headlines and story abstract

• Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones

  7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: TENX
  --- -------------- --- ------------- Total stockholders' equity $ 97,223,055 $ 8,098,107 Total liabilities and stockholders' equity $ 99,784,745 $ 11,684,627 === ============== === ============= Tenax Therapeutics, Inc. -- Consolidated Income Statement for the Periods Ended September 30, 2024 and September 30, 2023 Three months ended Nine months ended September September 30, 30, ------------------------- --------------------------- 2024 2023 2024 2023 Operating expenses General and administrative $ 1,506,796 $1,051,524 $ 4,083,858 $3,363,511 Research and development 3,112,085 1,065,855 8,115,370 1,529,493 ---------- --------- ---------- --------- Total operating expenses 4,618,881 2,117,379 12,199,228 4,893,004 Net operating loss 4,618,881 2,117,379 12,199,228 4,893,004 Interest expense 6,312 5,337 23,465 21,813 Interest income (664,724) (150,741) (887,057) (366,877) Other expense (income), net - - (654) (62,866) Net loss $ 3,960,469 $1,971,975 $11,334,982 $4,485,074 ========== ========= ========== ========= Net loss per share, basic and diluted $ 0.19 $ 6.61 $ 1.37 $ 19.36 Weighted average number of common shares and prefunded warrants outstanding, basic and diluted 21,161,143 298,280 8,282,118 231,653
  

• *DJ Tenax Therapeutics 3Q Loss/Shr 19c >TENX, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones

  7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: TENX